Colorectal cancer

Molecular characterisation of gastrointestinal tumours through genomic, transcriptomic and proteomic analysis (R. Salazar, V. Moreno).
Construction of molecular signatures for predicting colorectal cancer prognosis (R. Salazar).
Predictions of therapeutic response based on molecular tumour detection and subtype classification (R. Salazar)
New experimental therapeutic strategies to overcome resistance in colorectal cancer treatment (R. Salazar).
Research, evaluation and validation of new diagnostic biomarkers in colorectal cancer (V. Moreno).
Genetic and epigenetic determinants of susceptibility to CRC and chemotherapy toxicity (V. Moreno).
Improvement in cancer precision medication and biomarker identification using computational analysis and large-scale integration of molecular data. (X. Solé).
Stratification of CRC patients based on molecular characteristics and the level of immune-cell infiltration of their tumours (C. Santos andR. Sanz-Pamplona).
Microbiome-host interactions and colorectal cancer (V. Pimenoff, M. Obon, V. Moreno).
Prognostic and predictive values of circulating tumour DNA in metastatic colorectal cancer (C. Santos).

• Cortellini,A;Tabernero,J;Mukherjee,U;Salazar,R;Sureda,A;Maluquer,C;Ferrante,D et al, SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry, Lancet Oncol., 2023;24(4):335-346, doi:10.1016/S1470-2045(23)00056-6
• Tagliamento,M;Gennari,A;Lambertini,M;Salazar,R;Harbeck,N;Del Mastro,L;Aguilar Company,J et al, Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer, J. Clin. Oncol., 2023;41(15):2800-2814 doi:10.1200/JCO.22.01667
• Van Cutsem,E;Taieb,J;Yaeger,R;Yoshino,T;Grothey,A;Maiello,E;Elez,E et al, ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer., J. Clin. Oncol., 2023;41(14):2628-2637, doi:10.1200/JCO.22.01693
• Fernandez Rozadilla,C;Timofeeva,M;Chen,Z;Law,P;Thomas,M;Schmit,S;Díez Obrero,V et al, Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries., Nature Genet., 2023;55(1):89-99, doi:10.1038/s41588-022-01222-9
• Mahmood,K;Thomas,M;Qu,C;Gecco Ccfr,C;Hsu,L;Buchanan,DD;Peters,U, Elucidating the Risk of Colorectal Cancer for Variants in Hereditary Colorectal Cancer Genes., Gastroenterology, 2023;165(4):doi:10.1053/j.gastro.2023.06.032

• MCI21055. Federación de datos de salud: identificación inteligente de factores compartidos entre cáncer y enfermedades cardiovasculares para la mejorar prevención a lo largo de la vida (CC-Shared). Ministerio de Ciencia e Innovación. Budget: 524.400€. 2022-2024. PI: MORENO AGUADO, VICTOR RAUL.
• 18PSJ019. Genetic and metabolomics screening towards the precision medicine in cancer prevention (Genrisk). Asociación Española Contra el Cáncer (AECC). Budget: 500.000€. 2018-2024. PI: MORENO AGUADO, VICTOR RAUL.
• ERA21001. IMAGene: Epigenomic and machine learning models to predict pancreatic cancer: development of a new algorithm to integrate clinical, omics, DNA methylation biomarkers and environmental data for early detection of pancreatic cancer in high-risk individuals. Instituto de Salud Carlos III (ISCIII)/Asociación Española Contra el Cáncer (AECC). Budget: 304.687,96€. 2022-2025. PI: MORENO AGUADO, VICTOR RAUL.
• ERA21004. TANGERINE: Artificial-intelligence-based end-to-end prediction of cancer immunotherapy response. Instituto de Salud Carlos III (ISCIII) / Asociación Española Contra el Cáncer (AECC). Budget: 296.341€. 2022-2025. PI: MORENO AGUADO, VICTOR RAUL.
• 20FIS019. Refining the consensus molecular subtypes classification: prognostic and therapeutic implications in stage II colon cancer. Instituto de Salud Carlos III (ISCIII). Budget: 159.720€. 2020-2024. PI: Salazar Soler, Ramón.

Participation in international consortiums: MOTRICOLOR (Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer) and FIGI (Using functional genomics to inform gene environment interactions for CRC).
Colonomics as a platform for biomarker discovery and characterisation of CRC.
Clinical validation of ColoPrint®, a phase II prognostic genetic signature and new consensus on molecular subtype classification (CMS 1-4)